Sources_Sought_SNS_Pralidoxime.pdf

SNS Pralidoxime (Protopam) Sources Sought Notice

Document Type: Request for Information (RFI)

Release Date: June 6, 2019

Response Date: June 21st, 2019 by 3:00 p.m. EDT via email to

Caleb.Owen@hhs.gov

Description of Services/Supplies: Purchase of Pralidoxime (Protopam) IGM Powder Vial for

Injection

The Office of the Assistant Secretary for Preparedness and Response (ASPR) is conducting market research to identify potential sources that meet the requirements generally described in this notice as well as obtain feedback from industry. The intent of this announcement is to:

(a) Notify potential sources about the upcoming Pralidoxime buy

(b) Help ASPR identify interested vendors, particularly, but not limited to, small businesses,

(c) Obtain feedback from industry to assist ASPR in determining whether or not industry is capable of accomplishing the requirement.

This request is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of ASPR for any future solicitation. No official solicitation exists; therefore, please do not request a copy of a solicitation. If in the future an official solicitation is released, there is no guarantee that sources responding to this will be included on the source list.

Acknowledgement of receipt of responses will not be made, nor will respondents be notified of

ASPR’s view of the information received. Do not send any material that requires a non-disclosure agreement or that may be business sensitive. Responses to this solicitation will not be returned. This is strictly market research. There is no formal question and answer period and the Government may or may not respond to any questions received at its discretion.

I. Information Requested

Vendors interested in this RFI may provide a response (capability briefing) that includes the following information for ASPR internal use and consideration:

1. Company Name and Address

2. DUNS and TIN numbers

3. Point of Contact (Phone and Email)

4. NAICS code, business size, and socioeconomic status (if applicable)

5. Sufficient descriptive literature that unequivocally demonstrates the technically capability of the requested service to determine if the company can meet the requirement

6. Company’s availability via GSA or any other GWAC (if applicable)

SNS Pralidoxime (Protopam) Sources Sought Notice

7. Informational Pricing

8. Total package should not exceed fifteen (15) pages

II. Instructions for Submittal

Written responses shall be provided electronically, by 3:00 p.m. Eastern time on June 21st, 2019. The subject line of the e-mail message shall read: “SNS Pralidoxime Sources Sought

Response” and shall be addressed to Caleb.Owen@hhs.gov.

ASPR will not accept telephone, facsimile, courier, mail, or hand delivered responses. Further, access by ASPR to information in any files attached to a response is the responsibility of the submitting party. ASPR is not responsible for any failure to access information. Therefore, please ensure that files are easily accessible by ASPR – Microsoft Word or .pdf files are preferred.

ASPR will not notify respondents of the results of this market research. Information submitted will not be returned, and will not be accepted after the due date for responses.

Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted.

Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

mailto:Caleb.Owen@hhs.gov